Watching Panbela Therapeutics; Roth MKM Says "'Ipsen FDA Approval Of Onivyde In Pancreatic Cancer And Panbelas Earlier Phase 1/1b Results For Sbp-101 For The Same Indication Gives Investors Reason For Optimism.' Reiterate Buy And $25 Price Target"
Portfolio Pulse from Benzinga Newsdesk
Roth MKM has reiterated a 'Buy' rating and a $25 price target for Panbela Therapeutics (PBLA), citing optimism from Ipsen's FDA approval of Onivyde for pancreatic cancer and Panbela's promising early phase results for SBP-101 for the same indication.
February 14, 2024 | 7:52 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Roth MKM reiterates a 'Buy' rating and $25 price target for Panbela Therapeutics, optimistic about its SBP-101 for pancreatic cancer following Ipsen's Onivyde FDA approval.
The reiteration of a 'Buy' rating and a high price target by Roth MKM for Panbela Therapeutics is a strong positive signal for investors, especially in light of the optimism stemming from related developments in the treatment of pancreatic cancer. The approval of Ipsen's Onivyde and the promising early results of Panbela's SBP-101 for the same indication suggest potential for significant advancements and market impact. This analysis is based on the direct mention of Panbela's developments and the analyst's positive outlook.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100